Skip to main
EOLS

Evolus (EOLS) Stock Forecast & Price Target

Evolus (EOLS) Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 60%
Buy 20%
Hold 20%
Sell 0%
Strong Sell 0%

Bulls say

Evolus is a buy, with a positive outlook on their stock. The company's recent guidance reaffirms revenue and growth projections for 2026, with an expected increase in contribution from their injectable HA gel products. In addition, their long-term outlook suggests strong revenue growth and healthy EBITDA margins. Evolus' differentiated strategy and targeted marketing towards millennials positions them to maintain their market share despite competitive entrants. While potential risks exist, Evolus' solid performance in previous downturns and their expanding product portfolio supports a positive outlook.

Bears say

Evolus is a performance beauty company with commercially available injectable neurotoxins and hyaluronic acid (HA) gels. Key risks to our Buy rating include potential supply chain disruptions, competition from larger players, and dilution. However, we continue to hold a positive view on Evolus' positioning and expect the launch of the new product Sculpt to drive future growth. Additionally, the company's "bundling" strategy and discounts should help to capture market share from competitors like Voluma. Despite these strengths, we have a negative outlook on Evolus' stock due to potential risks and challenges in the competitive and regulatory landscape.

Evolus (EOLS) has been analyzed by 5 analysts, with a consensus rating of Buy. 60% of analysts recommend a Strong Buy, 20% recommend Buy, 20% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Evolus and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Evolus (EOLS) Forecast

Analysts have given Evolus (EOLS) a Buy based on their latest research and market trends.

According to 5 analysts, Evolus (EOLS) has a Buy consensus rating as of Jun 3, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $16.80, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $16.80, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Evolus (EOLS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.